One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Pfizer stands as one of the largest pharmaceutical companies in the world. Although it has an attractive 7.1% yield, it has a big blemish in its dividend past. Investors looking at drug stocks ...

Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long ...

NEW YORK: Top Pfizer communications executive Sally Susman is stepping down, effective at the end of the year. The company does not plan to replace Susman as EVP and chief corporate affairs officer.